Article
Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse.
Blood - 11 Oct 2018
Kim TaeHyung, Moon Joon Ho, Ahn Jae-Sook, Kim Yeo-Kyeoung, Lee Seung-Shin, Ahn Seo-Yeon, Jung Sung-Hoon, Yang Deok-Hwan, Lee Je-Jung, Choi Seung Hyun, Lee Ja-Yeon, Tyndel Marc S, Shin Myung-Geun, Lee Yoo Jin, Sohn Sang Kyun, Park Seong-Kyu, Zhang Zhaolei, Kim Hyeoung-Joon, Kim Dennis Dong Hwan
Abstract excerpt
Next-generation sequencing (NGS) has been applied to define clinically relevant somatic mutations and classify subtypes in acute myeloid leukemia (AML). Persistent allelic burden after chemotherapy is associated with higher relapse incidence, but presence of allelic burden in AML patients after receiving allogeneic hematopoietic cell transplantation (HCT) has not been examined longitudinally. As such, we aimed to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
